As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

ASHEVILLE — After going 9-4 and reaching the third round of the NCHSAA playoffs last season, Reynolds football retooled its offense. The Rockets added IMG Academy junior transfer quarterback Ely ...

(RTTNews) - Merck & Co., Inc. (MRK) and Daiichi ... small cell lung cancer or ES-SCLC. According to the companies, an objective response rate of 54.8% was observed with Daiichi Sankyo and Merck's ...

Merck (NYSE:MRK) and Daiichi Sankyo (OTCPK:DSNKY) (OTCPK:DSKYF) on Saturday announced interim results from a Phase 2 trial for lung cancer patients treated with ifinatamab deruxtecan (I-DXd ...

DURHAM – Nick Reynolds’ rookie season has an extremely impressive resume. State champion. State record holder. Now, he can add New England champion to that list. Reynolds, a Concord High ...

Based on three phase 2 trials of Daiichi Sankyo and AstraZeneca (NASDAQ:AZN)'s ENHERTU that showed clinically meaningful responses across a broad range of tumorsENHERTU now has... BASKING RIDGE ...

The companies' positive outlooks are supported by Daiichi Sankyo's advanced Antibody-Drug Conjugate (ADC) platform and its potential for significant growth. Enhertu, a breast cancer treatment ...